Korean Biotech at ESMO 2026 Madrid: Decoding the Cancer-Drug Data from ABL Bio, HLB, LigaChem Bio and More

🧬 K-Bio Heads to ESMO 2026 in Madrid: A Detailed Breakdown of the Cancer-Drug Data Being Played as a Trump Card

As autumn approaches, the biotech industry's attention naturally converges on one place: the world's top-tier stage in oncology—the study of cancer—the annual congress of the European Society for Medical Oncology. In 2026, ESMO 2026 will be held from October 23 to 27 at IFEMA, the large exhibition center in Madrid, Spain. To this stage, expected to draw more than 37,000 people from 174 countries, Korean pharmaceutical and biotech companies have one after another signaled their advance, each clutching its own cancer-drug report card. This article does not stop at listing which company is presenting what; it aims to look deeply at what that data actually means, and even at the perspectives we might easily overlook.

🏆 Why Is ESMO Called the "Oncology Olympics"?

First, it is worth examining the standing that the ESMO (European Society for Medical Oncology) stage holds. In the global cancer field, there are seats known as the "big three" congresses: the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO). Generally, AACR has a distinct character centered on basic and early-stage research, ASCO on comprehensive clinical work centered on the United States, and ESMO as a stage that represents Europe while also being flooded with global clinical data.

A concept helpful to know here is the hierarchy of presentation formats. Presentations at a congress are broadly divided into oral presentations and posters. An oral presentation is a format in which, among the countless studies submitted that year, those recognized as having high academic and clinical value are selected to be introduced directly on stage—so the selection itself is received as a kind of recognition. A poster, by contrast, is a method of posting research content on a wall, and tends to include more data that is relatively early-stage or supplementary in nature. Therefore, it is worth noting upfront that even for the same K-bio presentation, the weight the market assigns differs depending on whether it was chosen as an oral presentation or a poster.

📊 Three Keys to Decoding Cancer Data: ORR, PFS, and OS

Before examining each company's data in earnest, let me first organize the three evaluation metrics that appear without fail in cancer trials. Once you firmly grasp just these three, the numbers you will encounter going forward read much more clearly.

ORR (Objective Response Rate) refers to the proportion of patients whose tumor size shrank by a certain threshold or more after receiving treatment. It is the metric that most directly shows whether the drug elicited a response in the tumor. PFS (Progression-Free Survival) means the period during which, after treatment, the cancer held on without worsening—in other words, without progressing. OS (Overall Survival) is, literally, the metric indicating how long the patient survived, and it is regarded as the ultimate yardstick for evaluating a cancer drug.

Adding one insight here: there is a subtle tension among these three metrics. ORR and PFS can be confirmed at a relatively early point, whereas OS requires long-term patient follow-up and is heavily influenced by various external variables. Recently, the U.S. Food and Drug Administration (FDA) has shown a trend of increasingly emphasizing OS as a key metric, so the fact that OS data carries ever-greater weight in the cancer-drug approval process going forward serves as an important foundation for reading this ESMO.

💉 ABL Bio's "Tovecimig": Clear Light and Shadow Revealed in Biliary Tract Cancer

The K-bio presentation drawing the greatest attention at this ESMO can be said to be ABL Bio's tovecimig (development code ABL001). This candidate substance was licensed out to the U.S.-based Compass Therapeutics, and its Phase 2/3 results targeting biliary tract cancer have been selected for an oral presentation.

Tovecimig belongs to the bispecific antibody class. Whereas a typical antibody attacks only a single target, a bispecific antibody grabs two different targets at once. In tovecimig's case, it simultaneously aims at two things: DLL4 and VEGF-A. VEGF-A is a factor that spurs a tumor to create new blood vessels to supply itself with nutrients, and DLL4 is likewise a pathway involved in blood-vessel formation and tumor growth. Put simply, it is a strategy of blocking the tumor's supply lines from two directions at once.

In the COMPANION-002 trial, the ORR of the combination group given tovecimig together with paclitaxel (a long-used cancer drug) was 17.1%, greatly outpacing the 5.3% of the control group given paclitaxel alone. Median PFS also met statistical significance at 4.7 months for the combination group versus 2.6 months for the control group, and the risk of disease progression or death was lowered by as much as 56%. Up to here, it is a clear achievement.

However, on OS it failed to secure statistical significance, at 8.9 months for the combination group and 9.4 months for the control group. On the surface, this is a point that could appear to be a failure on the most important metric. But a concept that must absolutely be understood here is cross-over. Among the control-group patients, 54% switched to the tovecimig combination regimen after their disease progressed—and when this happens, the control-group patients too end up receiving the new drug's benefit, blurring the difference in survival period between the two groups. Compass judges that this very cross-over affected the OS result, and it plans to submit a BLA (Biologics License Application, the formal procedure to request approval to market a new drug) to the FDA within the year based on further analysis.

🩺 HLB's "Rivoceranib": Expanding Its Territory Beyond Liver Cancer to Thymic Epithelial Tumors

HLB, through its U.S. subsidiary Elevar Therapeutics, is presenting three studies concerning rivoceranib and lirafugratinib. Among them, what draws the eye is that an investigator-initiated Phase 2 trial of rivoceranib targeting previously treated patients with metastatic thymic epithelial tumors was selected for a "rapid oral presentation." A rapid oral presentation is a format that prioritizes announcing highly timely data, and it can be interpreted as a signal that the congress took notice to that degree.

Here, let me touch on the term investigator-initiated trial (IIT). This is a trial designed and led not by a pharmaceutical company but by a researcher at a medical institution, and it is often used to explore new indications (the range of diseases for which a drug can be used) for existing drugs. Since thymic epithelial tumors fall under rare cancers with few patients, this carries the meaning of gauging whether rivoceranib's range of use can be broadened.

In the liver-cancer domain, results analyzing how early antibiotic use affects treatment efficacy in CARES-310—the global Phase 3 trial of the rivoceranib and camrelizumab combination regimen—will be introduced as a poster. This is a part that calls for insight. Recently in oncology, the link between the gut microbiome environment and the responsiveness of immuno-oncology drugs has been a hot topic, and the hypothesis that antibiotics may disrupt the balance of gut microbes and thereby diminish immunotherapy efficacy has been steadily raised. HLB's analysis this time can be called a study that may offer practical hints to the clinical field in that context.

🎯 AimedBio and LigaChem Bio: A Precision-Strike Strategy Aimed with ADCs

AimedBio and LigaChem Bio put front and center the ADC (Antibody-Drug Conjugate), the technology that has risen most fervently in the cancer field recently. The easiest analogy for picturing an ADC is a guided missile. It is a method of attaching a powerful cancer drug—the payload—to an antibody that precisely recognizes only cancer cells, via a connecting link called a linker, so that the bomb is precisely delivered only to cancer cells while normal cells are left as untouched as possible. If the antibody is the guidance device that finds the target, the payload is the warhead with actual destructive power, and the linker is the joint connecting the two.

AimedBio's FGFR3-targeting ADC "AMB302" (Biohaven code BHV-1530), which it licensed out to the U.S.-based Biohaven, is disclosing additional Phase 1 data. What is noteworthy is the fact that early tumor reduction and responses were confirmed not only in patients with FGFR3 mutations, but also in patients who have no mutation but overexpress FGFR3. This means the patient population to which the drug can be applied may broaden considerably—an important signal in terms of commercial potential. On top of this, the fact that the major class toxicity seen with existing FGFR inhibitors has not yet been observed is also read positively in terms of safety.

LigaChem Bio is introducing, as a poster, the preclinical (animal and cell experiments conducted ahead of trials in humans) results and the global Phase 1/2 design of "LCB02A," an ADC aimed at claudin (CLDN) 18.2. CLDN18.2 is a protein that appears excessively on the cell surface of gastric cancer, pancreatic cancer, and others—an area with large treatment demand but a shortage of suitable drugs.

This candidate is characterized by applying LigaChem Bio's ADC platform "ConjuALL" to conjugate exatecan, a payload of the topoisomerase-1 inhibitor class. In that it is an attempt departing from the microtubule-inhibitor class it has focused on until now, it demonstrates technological evolution. It received IND (Investigational New Drug) approval from the FDA this past May, and with major domestic and international institutions—including the Dana-Farber Cancer Institute and Seoul National University Hospital—participating, it is aiming for its first patient dosing during the third quarter of this year.

🔬 Qurient and SillaJen: Foreshadowing the Next Chapter with Early-Phase Trials

Qurient and SillaJen present follow-up development strategies through Phase 1 data. Qurient is putting forth the results of a Phase 1 dose-escalation study (a study conducted by starting from a small amount and gradually increasing it to find the maximum dose that can be safely tolerated) of its CDK7 inhibitor "mocacyclib" targeting advanced solid tumors. CDK7 is an enzyme that regulates cell division and gene expression, and the principle is that inhibiting it can block the proliferation of cancer cells. Given that it has already fixed the recommended Phase 2 dose and is conducting a combination Phase 2 trial targeting hormone-receptor-positive, HER2-negative breast cancer patients, this presentation has a strong character of shoring up the grounds for advancing to the next stage.

SillaJen is presenting, as a poster, the Phase 1 results for "BAL0891" monotherapy and its paclitaxel combination regimen. Since it previously derived a recommended Phase 2 dose based on early data at ASCO 2026 this past May, this ESMO presentation appears set to be an occasion to confirm development progress along that same trajectory.

💡 The Questions from Other Angles That We Commonly Overlook

At this point, let me raise a few questions that are easy to pass over but must be asked.

First, the question "Does a congress presentation lead straight to a rise in the share price?" It does not. A congress presentation is merely an occasion to disclose data, and if the data is at a level the market already anticipated, it is not uncommon for it to be received instead as the dissipation of a catalyst, causing the share price to undergo a correction. The real crux lies in whether the absolute figures of the data exceed the market's expectations, and whether they become grounds leading to actual approval and commercialization.

Second, the question "If ORR and PFS are good, will OS naturally be good too?" As confirmed in the tovecimig case, that is not necessarily so. Factors in the trial design, such as cross-over, can blur OS, and amid a trend in which regulators increasingly value OS, how one explains and persuasively addresses this gap determines the success or failure of approval. This is precisely why one must read not only the numbers of the data but also the context in which those numbers emerged.

Third, the question "Whose achievement is the data of a licensed-out substance, really?" For tovecimig it is Compass, and for AMB302 it is Biohaven, that actually lead the trials. Since the domestic company's structure is to receive milestones—achievement bonuses by development stage—and royalties after handing over the substance, the partner firm's development will and capability, and how negotiations with the FDA unfold, directly affect the domestic company's value. In other words, when looking at K-bio's achievements, one must also examine who is holding the steering wheel.

🧭 In Closing

This ESMO 2026 is an opportunity to confirm, in one place, K-bio's attempt to broaden its presence on the global stage by leading with cutting-edge modalities (the manner or type by which a drug works)—bispecific antibodies and ADCs. From the late-stage trials of ABL Bio and HLB selected for oral presentations, to LigaChem Bio and AimedBio showing the evolution of ADC platforms, to Qurient and SillaJen preparing for the next stage, the development stages and strategies each differ. What matters is a gaze that coolly weighs what each piece of data means on the road toward actual approval and commercialization, and who is leading that journey—rather than being swept up by flashy presentation formats or individual figures.

This article was written for the purpose of conveying information; it is not investment advice recommending the purchase or sale of any specific stock. Judgments regarding investment and the responsibility that follows rest entirely with the investor, so before actually proceeding with an investment, please be sure to check disclosure materials and expert opinions together.